| metastatic/adv melanoma (mML) | |||
| mML - L1 - all population | mML - L1 - BRAF mutant | mML - L1 - BRAF wild | |
| Immune checkpoint association | |||
| nivolumab plus ipilimumab | CheckMate 067 ... CheckMate 069 ... CheckMate 067 ... | CheckMate 069 ... | CheckMate 069 ... |
| relatlimab plus nivolumab | RELATIVITY-047 | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
